On the other hand, the same amplitude of down-regulation of PTGES and PTGDR2 gene expression in the group with serous ovarian cancer grade G3 correlates with relapse-free survival at 6 months and the response to taxanes and platinum treatment, respectively (Figure S2B). Here, PTGDR2 is linked to ovarian serous adenocarcinoma.